Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders. The Company's lead compound is being developed to treat a psychiatric indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of unmet patient need. Promentis' drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress. In addition, Promentis has obtained an exclusive license from Marquette University and the University of Wisconsin - Milwaukee Research Foundation to certain intellectual property owned by Marquette University and the University of Wisconsin - Milwaukee Research Foundation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/31/17 | $26,000,000 | Series C |
Aisling Capital Black Pearl F-Prime Capital Partners Golden Angels Investors OrbiMed Advisors | undisclosed |
